Wilmington, Delaware, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Aimfinity Investment Corp. I (the "Company" or "AIMA") (Nasdaq: AIMAU), a special purpose acquisition company incorporated as a Cayman Islands exempted company, today announced that, in order to extend the date by which the Company mush complete its initial business combination from October 28, 2023 to November 28, 2023, I-Fa Chang, sole member and manager of the sponsor of the Company, has deposited into its trust account (the "Trust Account") an aggregate of $85,000 (the "Monthly Extension Payment").
Pursuant to the Company's second amended & restated memorandum and articles of association ("Current Charter"), effectively July 27, 2023, the Company may extend on a monthly basis from July 28, 2023 until April 28, 2024 or such an earlier date as may be determined by its board to complete a business combination by depositing the Monthly Extension Payment for each month into the Trust Account. This is the fourth of nine monthly extensions of the Company.
About Aimfinity Investment Corp. I
Aimfinity Investment Corp. I is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The Company has not selected any business combination target and has not, nor has anyone on its behalf, initiated any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with it. While the Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company, it will not complete its initial business combination with a target that is headquartered in China (including Hong Kong and Macau) or conducts a majority of its business in China (including Hong Kong and Macau).
Additional Information and Where to Find It
As previously disclosed, on October 13, 2023, the Company entered into that certain Agreement and Plan of Merger (as may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement"), by and between the Company, Docter Inc., a Delaware corporation (the "Company"), Aimfinity Investment Merger Sub I, a Cayman Islands exempted company and wholly-owned subsidiary of Parent ("Purchaser"), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of Purchaser ("Merger Sub"), pursuant to which the Company is proposing to enter into a business combination with Docter involving an reincorporation merger and an acquisition merger. This press release does not contain all the information that should be considered concerning the proposed business combination and is not intended to form the basis of any investment decision or any other decision in respect of the business combination. AIMA's stockholders and other interested persons are advised to read, when available, the proxy statement/prospectus and the amendments thereto and other documents filed in connection with the proposed business combination, as these materials will contain important information about AIMA, Purchaser or Docter, and the proposed business combination. When available, the proxy statement/prospectus and other relevant materials for the proposed business combination will be mailed to stockholders of AIMA as of a record date to be established for voting on the proposed business combination. Such stockholders will also be able to obtain copies of the proxy statement/prospectus and other documents filed with the Securities and Exchange Commission (the "SEC"), without charge, once available, at the SEC's website at www.sec.gov, or by directing a request to AIMA's principal office at 221 W 9th St, PMB 235 Wilmington, Delaware 19801.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended. Statements that are not historical facts, including statements about the pending transactions described herein, and the parties' perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the proposed transaction, including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the transactions. The words "expect," "believe," "estimate," "intend," "plan" and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.
Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the pending business combination, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate the businesses; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iv) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of AIMA or Docter; (v) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (vi) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of AIMA's securities; (vii) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Docter to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (viii): risks relating to the medical device industry, including but not limited to governmental regulatory and enforcement changes, market competitions, competitive product and pricing activity; and (ix) risks relating to the combined company's ability to enhance its products and services, execute its business strategy, expand its customer base and maintain stable relationship with its business partners.
A further list and description of risks and uncertainties can be found in the prospectus filed on April 26, 2022 relating to AIMA's initial public offering, the annual report of AIMA on Form 10-K for the fiscal year ended on December 31, 2022, filed on April 17, 2023, and in the Registration Statement/proxy statement that will be filed with the SEC by AIMA and/or its affiliates in connection with the proposed transactions, and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and Aimfinity, Docter, and their subsidiaries undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.
No Offer or Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of any potential transaction and does not constitute an offer to sell or a solicitation of an offer to buy any securities of AIMA, Purchaser or Docter, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act.
Participants in the Solicitation
AIMA, Docter, and their respective directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of AIMA's shareholders in connection with the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of AIMA's shareholders in connection with the proposed business combination will be set forth in the proxy statement/prospectus on Form F-4 to be filed with the SEC.
Contact Information:
Aimfinity Investment Corp. I
I-Fa Chang
Chief Executive Officer
221 W 9th St, PMB 235
Wilmington, Delaware 19801
特拉华州威尔明顿,2023 年 10 月 27 日(GLOBE NEWSWIRE)-- 作为开曼群岛豁免公司注册成立的特殊目的收购公司Aimfinity Investment Corp. I(“公司” 或 “AIMA”)(纳斯达克股票代码:AIMAU)今天宣布,为了将公司完成初始业务合并的日期从2023年10月28日延长至2023年11月28日,公司唯一成员兼保荐人的经理张义发已存入其信托账户(“信托账户”)总额为85,000美元(“每月延期付款”)。
根据公司第二次经修订和重述的组织章程大纲和章程(“现行章程”),自2023年7月27日起生效,公司可以从2023年7月28日起每月延长至2024年4月28日或董事会可能确定的更早日期,通过将每月的延期付款存入信托账户来完成业务合并。这是公司九个月延期中的第四次。
关于 Aimfinity 投资公司 I
Aimfinity Investment Corp. I 是一家作为开曼群岛豁免公司注册成立的空白支票公司,目的是与一个或多个企业或实体进行合并、股票交换、资产收购、股份购买、重组或类似的业务合并。公司没有选择任何业务合并目标,也没有人代表该公司就与其的初始业务合并与任何业务合并直接或间接启动任何实质性讨论。尽管公司在确定和收购目标公司时不会局限于特定的行业或地理区域,但它不会与总部位于中国(包括香港和澳门)或在中国(包括香港和澳门)开展大部分业务的目标完成初始业务合并。
其他信息以及在哪里可以找到
正如先前披露的那样,2023年10月13日,公司与特拉华州的一家公司 Docter Inc.(以下简称 “公司”)、Aimfinity Investment 合并子公司、开曼群岛豁免公司和母公司全资子公司(“买方”)和Aimfinity Investment Merger Sub之间签订了某些协议和合并计划(可能不时修订、补充或以其他方式修改,即 “合并协议”)特拉华州的一家公司,也是买方(“合并子公司”)的全资子公司,该公司据此收购方(“合并子公司”)提议与Docter进行业务合并,包括再公司合并和收购合并。本新闻稿不包含与拟议业务合并有关的所有应予考虑的信息,也无意构成任何投资决策或与业务合并有关的任何其他决策的基础。建议AIMA的股东和其他利益相关者在可能的情况下阅读委托书/招股说明书及其修正案以及与拟议业务合并有关的其他文件,因为这些材料将包含有关AIMA、买方或Docter以及拟议业务合并的重要信息。如果有,拟议业务合并的委托书/招股说明书和其他相关材料将在为拟议业务合并进行表决而确定的记录日期之前邮寄给AIMA的股东。此类股东还可以在美国证券交易委员会的网站www.sec.gov上免费获得向美国证券交易委员会(“SEC”)提交的委托书/招股说明书和其他文件的副本,也可以在19801年特拉华州威尔明顿PMB 235号西九街221号的AIMA总部提出申请。
前瞻性陈述
本新闻稿包含经修订的1933年《证券法》和《1934年《证券交易法》所指的某些 “前瞻性陈述”。非历史事实的陈述,包括有关本文所述待处理交易的陈述以及双方的观点和预期,均为前瞻性陈述。此类陈述包括但不限于有关拟议交易的陈述,包括预期的初始企业价值和收盘后权益价值、拟议交易的收益、整合计划、预期的协同效应和收入机会、预期的未来财务和运营业绩及业绩,包括增长估计、合并后公司的预期管理和治理以及预期的交易时间。“期望”、“相信”、“估计”、“打算”、“计划” 等词语表示前瞻性陈述。这些前瞻性陈述不能保证未来的表现,受已知或未知的各种风险和不确定性、假设(包括有关一般经济、市场、行业和运营因素的假设)的影响,这些假设可能导致实际结果与所示或预期的结果存在重大差异。
此类风险和不确定性包括但不限于:(i) 与待完成业务合并的预期时间和可能性相关的风险,包括由于交易的一个或多个成交条件未得到满足或免除,例如未按时或其他方式获得监管部门的批准,或政府实体禁止、延迟或拒绝批准完成交易或要求某些条件而导致交易无法完成的风险条件、限制或限制与此类批准相关的风险;(ii)与AIMA和Docter成功整合业务的能力相关的风险;(iii)可能导致适用交易协议终止的任何事件、变更或其他情况的发生;(iv)AIMA或Docter的财务状况、业绩、运营或前景可能发生重大不利变化的风险;(v)与管理时间中断相关的风险由于拟议交易而导致的持续业务运营;(vi) 任何风险与拟议交易有关的公告可能会对AIMA证券的市场价格产生不利影响;(vii)拟议交易及其公告有可能对Docter留住客户、留住和雇用关键人员以及与供应商和客户维持关系的能力以及他们的总体经营业绩和业务产生不利影响;(viii):与医疗器械行业相关的风险,包括但不限于政府的监管和执法变化、市场竞争,有竞争力的产品和定价活动;以及(ix)与合并后的公司增强产品和服务、执行业务战略、扩大客户群和与业务伙伴保持稳定关系的能力相关的风险。
风险和不确定性的进一步清单和描述可在2022年4月26日提交的与AIMA首次公开募股有关的招股说明书、AIMA于2023年4月17日提交的截至2022年12月31日财年的10-K表年度报告以及AIMA和/或其关联公司将向美国证券交易委员会提交的与拟议交易有关的注册声明/委托书以及双方可能提交的其他文件中找到向美国证券交易委员会提交或提供文件,鼓励您阅读。如果其中一项或多项风险或不确定性得以实现,或者如果基本假设被证明不正确,则实际结果可能与此类前瞻性陈述所表明或预期的结果存在重大差异。因此,提醒您不要过分依赖这些前瞻性陈述。前瞻性陈述仅与其发表日期有关,除非法律或适用法规要求,否则Aimfinity、Docter及其子公司没有义务更新前瞻性陈述以反映发表之日后的事件或情况。
不得提出要约或邀请
本新闻稿不是针对任何证券或任何潜在交易的委托声明或委托书、同意或授权的邀请,也不构成出售要约或招揽购买AIMA、Purchaser或Docter的任何证券的要约,在根据证券法进行注册或获得资格之前,此类要约、招标或销售属于非法的任何州或司法管辖区,也不得出售任何此类证券属于这样的州或司法管辖区。除非通过符合《证券法》要求的招股说明书,否则不得发行证券。
招标参与者
根据美国证券交易委员会的规定,AIMA、Docter及其各自的董事、执行官、其他管理层成员和员工可被视为参与就拟议交易征集AIMA股东代理人的活动。有关根据美国证券交易委员会的规定,可能被视为参与与拟议业务合并有关的AIMA股东招标的人员的信息,将在向美国证券交易委员会提交的F-4表格的委托书/招股说明书中列出。
联系我们 信息:
Aimfinity 投资公司 I
张怡发
首席执行官
221 W 9th St,PMB 235
特拉华州威尔明顿 19801